NCT04709393

Brief Summary

Hip fragility fractures are a major threat to functional independence in older adults locally and globally. In Hong Kong, the prevalence of osteoporosis and osteopenia in people aged \>50 years were reported to be as high as 37% and 52%, respectively. The major challenge in fragility fracture prevention is that fragility fracture is caused by the combination of osteoporosis and propensity to fall, and both of these conditions are multifactorial. Ample evidence shows that fall risks can be reduced by well-designed exercises, and osteoporosis can be effectively diagnosed by Dual-energy X-ray Absorptiometry imaging (DXA) and treated with anti-osteoporosis medication. Lifestyle modifications e.g. diet, optimal physical activity, environmental safety can also help to prevent falls or improve bone health. The brief Fracture Risk Assessment Tool (FRAX) and SARC-F provide a low cost of prescreening for fracture risk and sarcopenia, respectively. Using SARC-F in conjunction with FRAX has increased sensitivity for hip fracture risk prediction. FRAX+SARC-F may help increase the public awareness of osteoporosis and get the at-risk group to receive diagnostic tests and be treated. This model should fit in well with the coming District Health Centres across Hong Kong.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,956

participants targeted

Target at P75+ for not_applicable

Timeline
31mo left

Started May 2021

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress66%
May 2021Dec 2028

First Submitted

Initial submission to the registry

January 13, 2021

Completed
1 day until next milestone

First Posted

Study publicly available on registry

January 14, 2021

Completed
4 months until next milestone

Study Start

First participant enrolled

May 7, 2021

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2023

Completed
4.9 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2028

Expected
Last Updated

August 21, 2024

Status Verified

August 1, 2024

Enrollment Period

2.6 years

First QC Date

January 13, 2021

Last Update Submit

August 20, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • proportions of participants diagnosed with osteoporosis in the FRAX+SARC-F pre-screening and control groups.

    proportions of participants diagnosed with osteoporosis in the FRAX+SARC-F pre-screening and control groups.

    within 1-6 months

Secondary Outcomes (6)

  • Rate of receiving osteoporosis screening

    6-12 months

  • rate of receiving fall risk assessment

    6-12 months

  • rate of receiving anti-osteoporosis intervention

    6-12 months

  • rate of receiving fall prevention intervention

    6-12 months

  • subsequent fall rate

    12 months

  • +1 more secondary outcomes

Study Arms (2)

Pre-screening

EXPERIMENTAL

Receiving FRAX+SARC-F questionnaire pre-screening results on estimated fracture risk

Other: FRAX+SARC-F questionnaire pre-screening

Control

NO INTERVENTION

Not receiving FRAX+SARC-F questionnaire pre-screening preliminary results on estimated fracture risk

Interventions

Pre-screening group participants will receive the FRAX+SARC-F questionnaire pre-screening and be notified of the preliminary estimation of their future hip fracture risk before being invited to our DXA screening and fall-risk assessment.

Pre-screening

Eligibility Criteria

Age65 Years+
Sexall
Healthy VolunteersYes
Age GroupsOlder Adult (65+)

You may qualify if:

  • aged ≥ 65 years
  • living in the community

You may not qualify if:

  • cannot follow the instruction

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The Chinese University of Hong Kong Jockey Club Centre for Osteoporosis Care and Control

Hong Kong, Hong Kong

Location

MeSH Terms

Conditions

Osteoporosis

Condition Hierarchy (Ancestors)

Bone Diseases, MetabolicBone DiseasesMusculoskeletal DiseasesMetabolic DiseasesNutritional and Metabolic Diseases

Study Officials

  • Timothy Kwok

    The Chinese University of Hong Kong Jockey Club Centre for Osteoporosis Care and Control

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

January 13, 2021

First Posted

January 14, 2021

Study Start

May 7, 2021

Primary Completion

December 30, 2023

Study Completion (Estimated)

December 1, 2028

Last Updated

August 21, 2024

Record last verified: 2024-08

Locations